Pulmonary Fungal Infections

Pulmonary fungal infections arise when inhaled fungal spores colonize or invade the respiratory tract, often affecting individuals with weakened immune systems, chronic lung disease, or prolonged corticosteroid use. Common pathogens include Aspergillus, Histoplasma, Cryptococcus, and Coccidioides, each presenting with distinct clinical patterns ranging from mild respiratory illness to life-threatening disseminated disease. Pulmonary fungal infections often mimic bacterial or viral pneumonias, leading to diagnostic challenges. Accurate detection requires a combination of imaging studies, serological tests, fungal cultures, and molecular assays to confirm the specific pathogen. Treatment typically involves prolonged antifungal therapy with agents such as azoles, echinocandins, or amphotericin B, selected according to the organism and severity of disease. Invasive cases may require surgical intervention alongside pharmacologic therapy. Pulmonary fungal infections also highlight the importance of prevention in at-risk populations, including minimizing exposure to endemic environments and employing prophylactic antifungals in immunocompromised patients. Multidisciplinary care involving pulmonologists, infectious disease specialists, and critical care teams ensures comprehensive management, balancing effective therapy with monitoring for drug toxicity and resistance. Research continues to advance diagnostic methods, explore novel antifungal agents, and evaluate immunotherapeutic strategies aimed at improving outcomes. By integrating early recognition, targeted treatment, and preventive strategies, management of pulmonary fungal infections seeks to reduce morbidity and mortality, restore respiratory function, and improve survival in vulnerable patient groups.